Nicholas C P Cross Selected Research

Myeloproliferative Disorders (Myeloproliferative Disorder)

1/2008	Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders.
6/2007	Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.
5/2007	BCR-ABL-negative chronic myeloid leukemia.
4/2007	Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders.
2/2007	Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene.
2/2007	Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders.
1/2007	Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.
10/2006	Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene.
9/2006	International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
9/2005	Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nicholas C P Cross Research Topics

Disease

34	Neoplasms (Cancer) 01/2022 - 04/2006
22	Eosinophilia 01/2022 - 08/2002
17	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 06/2019 - 08/2002
15	Myeloproliferative Disorders (Myeloproliferative Disorder) 01/2008 - 01/2002
10	Systemic Mastocytosis 01/2022 - 11/2003
8	Polycythemia Vera 12/2019 - 04/2006
8	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2019 - 03/2003
8	Genetic Translocation (Chromosomal Translocation) 01/2016 - 08/2002
7	Hematologic Neoplasms (Hematological Malignancy) 01/2020 - 11/2003
6	Hypereosinophilic Syndrome (Loeffler Endocarditis) 03/2011 - 03/2003
5	BCR-ABL Negative Atypical Chronic Myeloid Leukemia (Leukemia, Myeloid, Philadelphia Negative) 09/2010 - 10/2004
5	Chromosome Aberrations (Chromosome Abnormalities) 02/2009 - 03/2003
4	Pdgfra-Associated Chronic Eosinophilic Leukemia 01/2020 - 04/2005
4	Primary Myelofibrosis (Myelosclerosis) 12/2019 - 06/2009
3	Mastocytosis 01/2021 - 04/2006
3	Anemia 11/2019 - 07/2013
3	Disease Progression 02/2015 - 12/2005
3	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 08/2011 - 04/2005
2	Leukemia 01/2022 - 03/2011
2	Thrombocytosis (Thrombocythemia) 01/2021 - 08/2013
2	Thrombocytopenia (Thrombopenia) 11/2019 - 10/2017
2	Philadelphia Chromosome 07/2017 - 11/2010
2	Chronic Neutrophilic Leukemia 01/2017 - 12/2005
2	Splenomegaly 09/2015 - 02/2011
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 11/2013 - 04/2012
2	Residual Neoplasm 07/2013 - 03/2005
2	Lymphoma (Lymphomas) 01/2012 - 01/2010
2	Multiple Myeloma 01/2012 - 12/2009
2	Acute Promyelocytic Leukemia 05/2010 - 04/2005
1	Myeloid Leukemia (Leukemia, Myelocytic) 01/2022
1	Essential Thrombocythemia 12/2019
1	Polycythemia (Erythrocytosis) 01/2018
1	Thrombosis (Thrombus) 10/2017
1	Hemorrhage 10/2017
1	Blast Crisis (Blast Phase) 09/2017
1	Ataxia Telangiectasia (Louis Bar Syndrome) 12/2016
1	Lymphadenopathy 09/2015
1	Ascites 09/2015
1	Carcinogenesis 06/2014
1	Mast-Cell Leukemia (Leukemia, Mast Cell) 10/2013
1	primary familial and congenital Polycythemia 08/2013
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2013
1	Schinzel-Giedion syndrome 01/2013

Drug/Important Bio-Agent (IBA)

32	Imatinib Mesylate (Gleevec)FDA Link 02/2020 - 08/2002
17	Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA 01/2020 - 08/2002
14	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2020 - 03/2003
11	Phosphotransferases (Kinase)IBA 12/2016 - 08/2002
11	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 07/2013 - 01/2002
9	Proteins (Proteins, Gene)FDA Link 01/2013 - 02/2004
7	Messenger RNA (mRNA)IBA 01/2022 - 10/2006
7	Tyrosine Kinase InhibitorsIBA 01/2020 - 08/2002
7	Tyrosine (L-Tyrosine)FDA Link 07/2013 - 05/2003
5	Tryptases (Tryptase)IBA 01/2022 - 09/2015
5	ruxolitinibIBA 01/2020 - 03/2013
4	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2022 - 05/2006
4	nilotinib FDA Link 01/2020 - 01/2011
3	midostaurinIBA 01/2022 - 01/2017
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2021 - 11/2007
3	Janus Kinase 2IBA 01/2021 - 04/2007
3	Dasatinib (BMS 354825)FDA Link 01/2020 - 01/2011
3	Hemoglobins (Hemoglobin)IBA 11/2019 - 07/2013
3	Erythropoietin FDA Link 01/2018 - 08/2013
3	InterferonsIBA 07/2017 - 01/2010
3	Indicators and Reagents (Reagents)IBA 04/2015 - 11/2010
3	DNA (Deoxyribonucleic Acid)IBA 07/2013 - 04/2005
3	Type 1 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 1)IBA 01/2008 - 02/2004
3	Pharmaceutical PreparationsIBA 04/2005 - 05/2003
2	LigandsIBA 12/2019 - 05/2004
2	Hydroxyurea (Hydrea)FDA LinkGeneric 07/2012 - 04/2012
2	nuclear pore complex protein 98IBA 01/2012 - 12/2005
2	Histones (Histone)IBA 01/2012 - 05/2011
2	Interferon-alpha (Interferon Alfa)IBA 01/2010 - 04/2006
1	Cladribine FDA LinkGeneric 01/2022
1	Alkaline PhosphataseIBA 01/2021
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2021
1	Interleukin-13IBA 01/2021
1	Cytokine Receptors (Cytokine Receptor)IBA 12/2019
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 12/2019
1	Interleukin-3 Receptors (Interleukin 3 Receptor)IBA 12/2019
1	avapritinibIBA 01/2019
1	Core Binding Factors (Core-Binding Factor)IBA 01/2019
1	Antisense OligonucleotidesIBA 12/2016
1	Cyclin BIBA 01/2016
1	CytosineIBA 01/2016
1	RNA Splice SitesIBA 01/2016
1	Biomarkers (Surrogate Marker)IBA 06/2014
1	Biological ProductsIBA 11/2013
1	Thrombopoietin (c-mpl Ligand)IBA 08/2013
1	Oxygen (Dioxygen)IBA 08/2013
1	fludarabineIBA 01/2013
1	Chlorambucil (Leukeran)FDA Link 01/2013
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2013
1	Codon (Codons)IBA 01/2013
1	Phosphorus (Red Phosphorus)IBA 04/2012
1	Busulfan (Busulfex)FDA Link 04/2012
1	Polycomb Repressive Complex 2IBA 02/2012

Therapy/Procedure

24	Therapeutics 06/2019 - 05/2003
4	Stem Cell Transplantation 09/2017 - 05/2006
2	Drug Therapy (Chemotherapy) 09/2017 - 09/2008
2	Aftercare (After-Treatment) 04/2005 - 08/2002